This is the authors' abstract. We don't add key points for this paper.
In this review, we discuss small-molecule, carbohydrate-based immunostimulants that target Toll-like receptor 4 (TLR-4) and cluster of differentiation 1D (CD1d) receptors. The design and use of these molecules in immunotherapy as well as results from their use in clinical trials are described. How these molecules work and their utilization as vaccine adjuvants are also discussed. Future applications and extensions for the use of these analogues as therapeutic agents will be outlined.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Marzabadi et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: